Halozyme Therapeutics (HALO) Intangibles (2022 - 2025)
Halozyme Therapeutics (HALO) has disclosed Intangibles for 4 consecutive years, with $981.5 million as the latest value for Q4 2025.
- Quarterly Intangibles rose 144.25% to $981.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $981.5 million through Dec 2025, up 144.25% year-over-year, with the annual reading at $981.5 million for FY2025, 144.25% up from the prior year.
- Intangibles for Q4 2025 was $981.5 million at Halozyme Therapeutics, up from $348.5 million in the prior quarter.
- The five-year high for Intangibles was $981.5 million in Q4 2025, with the low at $348.5 million in Q3 2025.
- Average Intangibles over 4 years is $551.3 million, with a median of $472.9 million recorded in 2023.
- The sharpest move saw Intangibles crashed 48.29% in 2023, then soared 144.25% in 2025.
- Over 4 years, Intangibles stood at $546.7 million in 2022, then decreased by 13.5% to $472.9 million in 2023, then dropped by 15.02% to $401.8 million in 2024, then surged by 144.25% to $981.5 million in 2025.
- According to Business Quant data, Intangibles over the past three periods came in at $981.5 million, $348.5 million, and $366.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.